EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOTSG00005028346
Gene Symbol: MAP3K12
1 Cross references
179 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOTSG00005006647
Gene Symbol: MAP3K12
1 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12-Like

Ensembl ID : ENSOTSG00005009185
Gene Symbol: LOC112215809
3 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSOTSG00005005509
Gene Symbol: MAP3K5
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5-Like

Ensembl ID : ENSOTSG00005021023
Gene Symbol: LOC112217549
3 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSOTSG00005033486
Gene Symbol: MAP3K8
3 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSOTSG00005035222
Gene Symbol: MAP3K8
1 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSOTSG00005005004
Gene Symbol: MAP3K9
1 Cross references
195 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSOTSG00005030042
Gene Symbol: MGLL
1 Cross references
202 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSOTSG00005045887
Gene Symbol: MGLL
1 Cross references
202 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSOTSG00005013233
Gene Symbol: MLNR
1 Cross references
174 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSOTSG00005030577
Gene Symbol: LOC112245281
2 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).